Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
CDTX
Cidara Therapeutics Inc.
$113.05
Login to see Cidara Therapeutics Inc. (CDTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Upgraded on attractively valued
Outperform the market
Risk Analysis
Earnings are forecast to decrease
Chart
$64.71 (+74.70%)
$57.05 (+98.16%)
$26.25 (+330.67%)
$12.6 (+797.22%)
CDTX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
CDTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
Outperform the market
CDTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CDTX Street view is extremely bullish but have mixed views on the near-term outlook
Average key support and resistance price levels.
Login to displayCDTX Earnings
The TTM reflects 12-month period, providing review of CDTX financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is CDTX current stock price?
What are CDTX stock strengths?
What risks are associated with CDTX stock?
When is CDTX next earnings report?
What is CDTX market cap and volume?
What is CDTX's current Stock IQ?
Should I buy CDTX stock right now?
Is CDTX a Strong Buy right now?
What does a 'Strong Buy' rating mean for CDTX?
What does a 'Strong Sell' rating mean for CDTX?
What factors influence CDTX's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+16.05%
-12.55%
-15.72%
-2.98%
CDTX
Cidara Therapeutics Inc.
Current Price
$113.05
Stock Insights
Strengths
Upgraded on attractively valued
Outperform the market
Risk Analysis
Earnings are forecast to decrease
Login to unlock Cidara Therapeutics Inc. (CDTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$64.71 (+74.70%)
$57.05 (+98.16%)
$26.25 (+330.67%)
$12.6 (+797.22%)
CDTX Analysts Opinion
CDTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to decrease
Outperform the market
CDTX Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
CDTX Street view is extremely bullish but have mixed views on the near-term outlook
CDTX has Extreme Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
High volatilty
Average key support and resistance price levels.
Login to displayCDTX Earnings
The TTM data reflects the most recent 12-month period, providing overview of CDTX financial performance.
CDTX Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
CDTX Latest Analysis
JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation. Fintel reports that on October 10 2025 JP Morgan initiated coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Overweight recommendation. Analyst Price Forecast Suggests 21.25% Upside
Today
CDTX Stock Up on FDAs Breakthrough Therapy Tag for CD388 in Influenza. Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Today
Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage. ) shares are trading higher on Friday after the biotech company made a recent announcementabout their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock assigning it an Overweight rating and .
Today
Cidara Therapeutics Analyst Says Lead Influenza Candidate Is Strategically Attractive. JP Morgan initiated coverage of ) on Friday citing its lead asset CD388 for influenza underscoring the game-changing potential of the product and multi-billion dollar .Analyst Anupam Rama says across doses prevention efficacy was ahead of known vaccine benchmarks across various populations with the highest dose (450mg) showing a prevention efficacy of around 76% with no major safety concerns.In June the compan
Today
HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation. Fintel reports that on October 9 2025 HC Wainwright &. Co. maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside
Today
WBB Securities Maintains Cidara Therapeutics (CDTX) Strong Buy Recommendation. Fintel reports that on October 9 2025 WBB Securities maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Strong Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside
Today
Why Cidara Therapeutics Stock Crushed It Today. Key PointsIt reported some highly encouraging news about its leading drug candidate.
Thu Oct 9, 2025
Cidara Therapeutics Says FDA Grants Breakthrough Therapy Designation For CD388 For Influenza A And B . (RTTNews) - Biotechnology company Cidara Therapeutics Inc. (CDTX) announced Thursday that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in adults and adolescents who are at higher risk of in
Thu Oct 9, 2025
FDA Grants Breakthrough Therapy Status To Cidaras CD388 For Prevention Of Influenza A And B . (RTTNews) - Cidara Therapeutics Inc. (CDTX) on Thursday said that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for CD388 for prevention of influenza A and B in high-risk adults and adolescents.
Thu Oct 9, 2025
H.C. Wainwright reiterates Buy rating on Cidara Therapeutics stock.
Fri Oct 3, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CDTX Stock trends
CDTX Stock performance
CDTX Stock analysis
CDTX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings
Leaders